FeesSafety
Pluang+

Bitcoin derivatives wallet with $38.2M losses opens $6.45M short position after closing long trade

Technical Signals
03 Nov 2026, 11:35 WIB
Tokenpost
View Source
Neutral
Bitcoin derivatives wallet with $38.2M losses opens $6.45M short position after closing long trade

A Bitcoin derivatives wallet that has accumulated about $38.2 million in losses recently shifted its market stance by closing a long position worth $6.88 million and opening a new short position valued at approximately $6.45 million. This change means the wallet is now positioned to benefit if Bitcoin's price falls, reversing its previous bet on price increases. The $38.2 million figure represents total losses over time, not losses from the new short position. This activity highlights significant trading shifts in the Bitcoin derivatives market.

The Bitcoin derivatives wallet's recent $6.45 million short position and $38.2 million total losses provide context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 03, 2026 16:41 WIB: out of 50 priced assets, only 7 rose while 42 fell. Notably, Stellar (XLM) dropped 3.90% to Rp2.930 with a 99% sell order activity, Zilliqa (ZIL) declined 3.62% to Rp32 with 63% sell orders, contrasting with Cosmos (ATOM) which fell 3.19% to Rp25.963 but saw 96% buy orders and a typical hold time of 61 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
45 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
45 minutes ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
45 minutes ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
1 hour ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App